View in EDS HTML Full Text PDF Full Text

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.

Saved in:
Bibliographic Details
Title: Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.
Authors: Ribeiro AJS; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Guth BD; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa., Engwall M; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States., Eldridge S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Foley CM; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Guo L; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Gintant G; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Koerner J; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Parish ST; Health and Environmental Sciences Institute, Washington, DC, United States., Pierson JB; Health and Environmental Sciences Institute, Washington, DC, United States., Brock M; Department of Safety Assessment, Genentech, South San Francisco, CA, United States., Chaudhary KW; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States., Kanda Y; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan., Berridge B; National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States.
Source: Frontiers in pharmacology [Front Pharmacol] 2019 Aug 29; Vol. 10, pp. 934. Date of Electronic Publication: 2019 Aug 29 (Print Publication: 2019).
Publication Type: Journal Article; Review
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31555128
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ribeiro+AJS%22">Ribeiro AJS</searchLink>; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.<br /><searchLink fieldCode="AU" term="%22Guth+BD%22">Guth BD</searchLink>; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa.<br /><searchLink fieldCode="AU" term="%22Engwall+M%22">Engwall M</searchLink>; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Eldridge+S%22">Eldridge S</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.<br /><searchLink fieldCode="AU" term="%22Foley+CM%22">Foley CM</searchLink>; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States.<br /><searchLink fieldCode="AU" term="%22Guo+L%22">Guo L</searchLink>; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.<br /><searchLink fieldCode="AU" term="%22Gintant+G%22">Gintant G</searchLink>; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States.<br /><searchLink fieldCode="AU" term="%22Koerner+J%22">Koerner J</searchLink>; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.<br /><searchLink fieldCode="AU" term="%22Parish+ST%22">Parish ST</searchLink>; Health and Environmental Sciences Institute, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Pierson+JB%22">Pierson JB</searchLink>; Health and Environmental Sciences Institute, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Brock+M%22">Brock M</searchLink>; Department of Safety Assessment, Genentech, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Chaudhary+KW%22">Chaudhary KW</searchLink>; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States.<br /><searchLink fieldCode="AU" term="%22Kanda+Y%22">Kanda Y</searchLink>; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Berridge+B%22">Berridge B</searchLink>; National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2019 Aug 29; Vol. 10, pp. 934. <i>Date of Electronic Publication: </i>2019 Aug 29 (<i>Print Publication: </i>2019).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31555128
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fphar.2019.00934
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 934
    Titles:
      – TitleFull: Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ribeiro AJS
      – PersonEntity:
          Name:
            NameFull: Guth BD
      – PersonEntity:
          Name:
            NameFull: Engwall M
      – PersonEntity:
          Name:
            NameFull: Eldridge S
      – PersonEntity:
          Name:
            NameFull: Foley CM
      – PersonEntity:
          Name:
            NameFull: Guo L
      – PersonEntity:
          Name:
            NameFull: Gintant G
      – PersonEntity:
          Name:
            NameFull: Koerner J
      – PersonEntity:
          Name:
            NameFull: Parish ST
      – PersonEntity:
          Name:
            NameFull: Pierson JB
      – PersonEntity:
          Name:
            NameFull: Brock M
      – PersonEntity:
          Name:
            NameFull: Chaudhary KW
      – PersonEntity:
          Name:
            NameFull: Kanda Y
      – PersonEntity:
          Name:
            NameFull: Berridge B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 08
              Text: 2019 Aug 29
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 1663-9812
          Numbering:
            – Type: volume
              Value: 10
          Titles:
            – TitleFull: Frontiers in pharmacology
              Type: main
ResultId 1